Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis

American Journal of Hematology

Volumn 83, Issue 7, 2008, Pages 593-595

  Avarbock, Andrew B ^a   Loren, Alison W ^a   Park, Jason Y ^a   Junkins Hopkins, Jacqueline M ^a   Choi, John ^a   Litzky, Leslie A ^a   Rook, Alain H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CEFEPIME; DENILEUKIN DIFTITOX; DEXAMETHASONE; HYPERTENSIVE FACTOR; VANCOMYCIN;

ACIDOSIS; ADULT; ALBUMIN BLOOD LEVEL; ANAMNESIS; ARTICLE; CANCER PATIENT; CASE REPORT; CHILL; CUTANEOUS T CELL LYMPHOMA; CYANOSIS; DETERIORATION; DIZZINESS; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEVER; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOTENSION; LIVER CIRRHOSIS; MALE; MYALGIA; NIGHT SWEAT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RHABDOMYOLYSIS; SIDE EFFECT; SYNCOPE; URINE CULTURE; VASCULAR LEAK SYNDROME;

DIPHTHERIA TOXIN; FATAL OUTCOME; FIBROSIS; HUMANS; INTERLEUKIN-2; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; SYNDROME; TREATMENT FAILURE; VASCULAR DISEASES;

EID: 45749140159     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21180     Document Type: Article

References (25)

1. LeMaistre CF, Meneghetti C, Rosenblum M, et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992;79:2547-2554.
2. Dang NH, Hagemeister FB, Pro B, et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2004;22:4095-4102.
3. Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007;136:439-447.
4. Frankel AE, Fleming DR, Hall PD, et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 2003;9:3555-3561.
5. Shaughnessy PJ, Bachier C, Grimley M, et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:188-193.
6. Railan D, Fivenson DP, Wittenberg G. Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma. J Am Acad Dermatol 2000;43:323-324.
7. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-388.
8. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785.
9. Kinney MC, Jones D. Cutaneous T-cell and NK-cell lymphomas: The WHO-EORTC classification and the increasing recognition of specialized tumor types. Am J Clin Pathol 2007;127:670-686.
10. LeMaistre CF, Saleh MN, Kuzel et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998;91:399-405.
11. Kagan BL, Finkelstein A, Colomblni M. Diphtheria toxin fragment forms large pores in phospholipid bilayer membranes. Proc Natl Acad Sci USA 1981;78:4950-4954.
12. Nakase K, Kita K, Nasu K, et al. Differential expression of interleukin-2 receptors (α and α chain) in mature lymphoid neoplasms. Am J Hematol 1994;46:179-183.
13. Bechard DE, Gudas SA, Sholley MM, et al. Nonspecific cytotoxicity of recombinant interleukin-2 activated lymphocytes. Am J Med Sci 1989;298:28-33.
14. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
15. Dutcher JP, Gaynor ER, Boldt DH, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991;9:641-648.
16. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
17. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Saf 1992;7:417-433.
18. Baluna R, Vitetta ES. Vascular leak syndrome: A side effect of immunotherapy. Immunopharmacology 1997;37:117-132.
19. Baluna R, Rizo J, Gordon BE, et al. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci USA 1999;96:3957-3962.
20. Vitetta ES, Stone M, Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991;51:4052-4058.
21. Foss FM, Bacha P, Osann KE, et al. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: Decreased frequency and severity with steroid premedication. Clin Lymphoma 2001;1:298-302.
22. Rosenberg SA, Lotze MT. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 1986;4:681-709.
23. Dolberg-Stolik OC, Putterman C, Rubinow A, et al. Idiopathic capillary leak syndrome complicated by massive rhabdomyolysis. Chest 1993;104:123-126.
24. Rigamonti C, Mottaran E, Reale E, et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 2003;38:42-49.
25. Wallaert B, Colombel JF, Prin L, et al. Bronchoalveolar lavage in alcoholic liver cirrhosis. T-lymphocyte subsets and immunoglobulin concentrations. Chest 1992;101:468-473.